Screening Methods of
                       Bronchodilators




Guided By:                                Presented By:
Mr. Rupesh Gautam                        Prafulla Chandra Tiwari
Senior Lecturer, Dept. of Pharmacology   M.Pharm Pharmacology
Jaipur College of Pharmacy               Jaipur College of Pharmacy



    11/1/2012                                                     1
Bronchodilators
The pharmacological therapy of asthma employs
drugs aimed more directly at decreasing
bronchospasm (i.e., bronchodilators).

The main drugs used as bronchodilators are β2-
adrenoceptor agonists; others include xanthines,
cysteinyl leukotriene receptor antagonists and
muscarinic receptor antagonists.


11/1/2012                                     2
β2 Adrenergic Receptor Agonists
   The β adrenergic receptor agonists available for the
    treatment of asthma are selective for the β2 -receptor
    subtype.
   The mechanism of the antiasthmatic action of β2
    adrenergic receptor agonists the direct relaxation of
    airway smooth muscle and consequent bronchodilation




 11/1/2012                                                 3
Theophylline
 • It inhibits phosphodiesterase and blocks adenosine
   receptors.
 • Theophylline has a narrow therapeutic window:
   unwanted effects include cardiac dysrhythmia,
   seizures and gastrointestinal disturbances.
 • It is given intravenously (by slow infusion) for
   status asthmaticus, or orally (as a sustained-release
   preparation) as add-on therapy to inhaled
   corticosteroids and long-acting β2 agonists


11/1/2012                                             4
Screening Models of Bronchodilators
  1.Bronchospasmolytic activity in anesthetized guinea
     pigs (Konzett-Rössler method)

  2. Effect of arachidonic acid or PAF on respiratory
     function in vivo

  3. Bronchial hyperreactivity

  4.Body plethysmography and respiratory parameters
  after histamine-induced    bronchoconstriction in
  anesthetized guinea pigs.

  5. Pneumotachography in anesthetized guinea pigs
11/1/2012                                            5
Bronchospasmolytic activity in anesthetized
guinea pigs (Konzett-Rössler method)
PURPOSE AND RATIONALE:
•The method is based on registration of air volume changes of a
living animal in a closed system consisting of the respiration
pump.


•Bronchospasm decreases the volume of inspired air and increases
the volume of excess air.


•Thus, the degree of bronchospasm can be quantified by recording
the volume of
excess air.
Procedure:
  •Guinea-pigs of either sex weighing 250–500 g are
  anaesthetized with 1.25 g/kg i.p. urethane.

  •The trachea is cannulated by means of a two way cannula,
  one arm of which is connected to the respiratory pump and
  the other to a Statham P23 Db transducer.

  •The animal is artificially respired using a Starling pump
  with an inspiratory pressure set at 90–120 mm of water, an
  adequate tidal volume of 3 ml/100 g body weight and a
  frequency of 60 strokes per minute.

11/1/2012                                                      7
•Excess air, not taken up by the lungs, is
measured and recorded on a polygraph

• The internal jugular vein is cannulated
for the administration of spasmogens and
test compounds.

• The carotid artery is cannulated for
measuring blood pressure.
11/1/2012                                8
Effect of arachidonic acid or PAF on
respiratory function in vivo

 PURPOSE AND RATIONALE:

 The test allows to evaluate the sites of action of drugs,
 which interfere with the mechanisms of broncho-
 constriction and thrombocytopenia; in an in vivo-
 model guinea pigs are challenged with the spasmogens
 and platelet-aggregating substances arachidonic acid
 or PAF (platelet activating factor).
Procedure:

1.Male guinea pigs (Pirbright White) weighing 300–600 g are
   anesthetized with 60 mg/kg pentobarbital sodium (i.p.).

2. One of the jugular veins is cannulated for the administration
of spasmogen and test compound.

3. Both external carotid arteries are cannulated; one is connected
to a pressure transducer to register blood pressure, the other is
used for blood withdrawal.

4.The trachea is connected to a Starling pump with an
inspiratory pressure set of 80 mm H2O, an adequate tidal volume
of approx. 10 ml/kg body weight and a frequency of 70–75
strokes/ min.
5. Spontaneous respiration is inhibited by intravenous injection
of pancuronium (4 mg/kg) or gallamine (2 mg/kg) on time.


6. In some experiments, pulmonal ß-receptors are blocked by
intraperitoneal administration of propranolol (2 mg/kg).


7. Excess air, not taken up by the lungs, is conducted to a
transducer with bronchotimer, which translates changes in air
flow to an electrical signal.


8. Changes in air flow and arterial blood pressure are recorded
continuously.
Bronchial hyper reactivity

PURPOSE AND RATIONALE:

• Symptoms like asphyctic convulsions resembling bronchial
asthma in patients can be induced by inhalation of histamine or
other bronchospasm inducing agents in guinea pigs.

•The challenging agents are applied as aerosols produced by an
ultra-sound nebulizer

• The first symptoms are increased breathing frequency, forced
inspiration, and finally asphyctic convulsions.
•The occurrence of these symptoms can be delayed by
antagonistic drugs.
• Pre-convulsion  time, i.e. time   until   asphyctic
convulsions, can be measured.
PROCEDURE
•Ten male albino guinea pigs weighing 300–400 g per
group are used. The inhalation cages consist of 3
boxes each ventilated with an air flow of 1.5 l/min.

• The animal is placed into box A to which the test
drug or the standard is applied using an ultra-sound
nebulizer.

•Alternatively, the animal is treated orally or
subcutaneously with the test drug or the standard.
Box B serves as a sluice through which the animal is
passed into box C.

There, the guinea pig is exposed to an aerosol of a 0.1%
solution of histamine hydrochloride provided by an
ultra-sound nebulizer.

Time until appearance of asphyctic convulsions is
measured. Then, the animal is immediately withdrawn
from the the inhalation box. The aerosols are removed
from the back wall of the boxes by applying
low pressure.
Bibliography:

1.Goodman     Gilman,    Pharmacological     Basis   of
Therapeutics,11th Edition. Published by Mc-Graw Hill.
2.Vogel H. Gerhard, “Drug Discovery and Evaluation”,
  Second Edition, Published by Springer. Page No. 359-
  368.
3.Kagoshima M, Tomomatsu N, Iwahisha Y, Yamaguchi
S, Matsuura(1997) Suppressive effects of Y-24180, a
receptor antagonist to platelet activating factor (PAF),
on antigen-induced asthmatic responses in guinea pigs.
Inflamm Res 46:147–153.
Screening Models of Bronchodilator
Screening Models of Bronchodilator

Screening Models of Bronchodilator

  • 1.
    Screening Methods of Bronchodilators Guided By: Presented By: Mr. Rupesh Gautam Prafulla Chandra Tiwari Senior Lecturer, Dept. of Pharmacology M.Pharm Pharmacology Jaipur College of Pharmacy Jaipur College of Pharmacy 11/1/2012 1
  • 2.
    Bronchodilators The pharmacological therapyof asthma employs drugs aimed more directly at decreasing bronchospasm (i.e., bronchodilators). The main drugs used as bronchodilators are β2- adrenoceptor agonists; others include xanthines, cysteinyl leukotriene receptor antagonists and muscarinic receptor antagonists. 11/1/2012 2
  • 3.
    β2 Adrenergic ReceptorAgonists  The β adrenergic receptor agonists available for the treatment of asthma are selective for the β2 -receptor subtype.  The mechanism of the antiasthmatic action of β2 adrenergic receptor agonists the direct relaxation of airway smooth muscle and consequent bronchodilation 11/1/2012 3
  • 4.
    Theophylline • Itinhibits phosphodiesterase and blocks adenosine receptors. • Theophylline has a narrow therapeutic window: unwanted effects include cardiac dysrhythmia, seizures and gastrointestinal disturbances. • It is given intravenously (by slow infusion) for status asthmaticus, or orally (as a sustained-release preparation) as add-on therapy to inhaled corticosteroids and long-acting β2 agonists 11/1/2012 4
  • 5.
    Screening Models ofBronchodilators 1.Bronchospasmolytic activity in anesthetized guinea pigs (Konzett-Rössler method) 2. Effect of arachidonic acid or PAF on respiratory function in vivo 3. Bronchial hyperreactivity 4.Body plethysmography and respiratory parameters after histamine-induced bronchoconstriction in anesthetized guinea pigs. 5. Pneumotachography in anesthetized guinea pigs 11/1/2012 5
  • 6.
    Bronchospasmolytic activity inanesthetized guinea pigs (Konzett-Rössler method) PURPOSE AND RATIONALE: •The method is based on registration of air volume changes of a living animal in a closed system consisting of the respiration pump. •Bronchospasm decreases the volume of inspired air and increases the volume of excess air. •Thus, the degree of bronchospasm can be quantified by recording the volume of excess air.
  • 7.
    Procedure: •Guinea-pigsof either sex weighing 250–500 g are anaesthetized with 1.25 g/kg i.p. urethane. •The trachea is cannulated by means of a two way cannula, one arm of which is connected to the respiratory pump and the other to a Statham P23 Db transducer. •The animal is artificially respired using a Starling pump with an inspiratory pressure set at 90–120 mm of water, an adequate tidal volume of 3 ml/100 g body weight and a frequency of 60 strokes per minute. 11/1/2012 7
  • 8.
    •Excess air, nottaken up by the lungs, is measured and recorded on a polygraph • The internal jugular vein is cannulated for the administration of spasmogens and test compounds. • The carotid artery is cannulated for measuring blood pressure. 11/1/2012 8
  • 9.
    Effect of arachidonicacid or PAF on respiratory function in vivo PURPOSE AND RATIONALE: The test allows to evaluate the sites of action of drugs, which interfere with the mechanisms of broncho- constriction and thrombocytopenia; in an in vivo- model guinea pigs are challenged with the spasmogens and platelet-aggregating substances arachidonic acid or PAF (platelet activating factor).
  • 10.
    Procedure: 1.Male guinea pigs(Pirbright White) weighing 300–600 g are anesthetized with 60 mg/kg pentobarbital sodium (i.p.). 2. One of the jugular veins is cannulated for the administration of spasmogen and test compound. 3. Both external carotid arteries are cannulated; one is connected to a pressure transducer to register blood pressure, the other is used for blood withdrawal. 4.The trachea is connected to a Starling pump with an inspiratory pressure set of 80 mm H2O, an adequate tidal volume of approx. 10 ml/kg body weight and a frequency of 70–75 strokes/ min.
  • 11.
    5. Spontaneous respirationis inhibited by intravenous injection of pancuronium (4 mg/kg) or gallamine (2 mg/kg) on time. 6. In some experiments, pulmonal ß-receptors are blocked by intraperitoneal administration of propranolol (2 mg/kg). 7. Excess air, not taken up by the lungs, is conducted to a transducer with bronchotimer, which translates changes in air flow to an electrical signal. 8. Changes in air flow and arterial blood pressure are recorded continuously.
  • 12.
    Bronchial hyper reactivity PURPOSEAND RATIONALE: • Symptoms like asphyctic convulsions resembling bronchial asthma in patients can be induced by inhalation of histamine or other bronchospasm inducing agents in guinea pigs. •The challenging agents are applied as aerosols produced by an ultra-sound nebulizer • The first symptoms are increased breathing frequency, forced inspiration, and finally asphyctic convulsions.
  • 13.
    •The occurrence ofthese symptoms can be delayed by antagonistic drugs. • Pre-convulsion time, i.e. time until asphyctic convulsions, can be measured.
  • 14.
    PROCEDURE •Ten male albinoguinea pigs weighing 300–400 g per group are used. The inhalation cages consist of 3 boxes each ventilated with an air flow of 1.5 l/min. • The animal is placed into box A to which the test drug or the standard is applied using an ultra-sound nebulizer. •Alternatively, the animal is treated orally or subcutaneously with the test drug or the standard.
  • 15.
    Box B servesas a sluice through which the animal is passed into box C. There, the guinea pig is exposed to an aerosol of a 0.1% solution of histamine hydrochloride provided by an ultra-sound nebulizer. Time until appearance of asphyctic convulsions is measured. Then, the animal is immediately withdrawn from the the inhalation box. The aerosols are removed from the back wall of the boxes by applying low pressure.
  • 16.
    Bibliography: 1.Goodman Gilman, Pharmacological Basis of Therapeutics,11th Edition. Published by Mc-Graw Hill. 2.Vogel H. Gerhard, “Drug Discovery and Evaluation”, Second Edition, Published by Springer. Page No. 359- 368. 3.Kagoshima M, Tomomatsu N, Iwahisha Y, Yamaguchi S, Matsuura(1997) Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs. Inflamm Res 46:147–153.